MLNT Melinta Therapeutics Inc.

13.00
-0.20  -2%
Previous Close 13.20
Open 13.40
Price To book 2.84
Market Cap 407230863
Shares 31,325,451
Volume 99,680
Short Ratio 6.36
Av. Daily Volume 147,190

SEC filingsSee all SEC filings

  1. EFFECT - Notice of Effectiveness 18579154
  2. S-3 - Registration statement under Securities Act of 1933 18552507
  3. EFFECT - Notice of Effectiveness 18546559
  4. EFFECT - Notice of Effectiveness 18546557
  5. EFFECT - Notice of Effectiveness 18546560

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 enrollment to be completed 2H 2018.
Topical Radezolid
Acne vulgaris
Melinta plans to continue to explore the potential use - noted mid December 2017.
Taksta - Fusidic acid
Refractory infections in bones and joints
CRL announced December 29, 2016. Further trials required.
Solithera - intravenous
Community-acquired bacterial pneumonia (CABP)
CRL announced December 29, 2016. Further trials required.
Solithera - oral
Community-acquired bacterial pneumonia (CABP)
Phase 2 interim data released September 30, 2016. Noted February 28, 2017 that development has been suspended due to lack of efficacy.
Solithromycin
NASH
Phase 3 initiated August 2014. Enrollment completed December 2015 but decided to increase enrollment. Noted January 9, 2017 that extension enrollment has been slower than envisaged. Finally noted February 28, 2017 that data did not demonstrate non-inferiority (NI) to standard of care.
Solithromycin
Uncomplicated urogenital gonococcal infections
Phase 3 data released February 24, 2017 - endpoints met. Second Phase 3 trial to be initiated.
Taksta - Fusidic acid
Acute bacterial skin and skin structure infections (ABSSSI)
Phase 2 trial discontinued - noted January 9, 2017.
Solithromycin
COPD

Latest News

  1. Wired News – Melinta Launched Intravenous and Oral Formulations of Baxdela(TM) in the US
  2. Melinta Therapeutics Launches Antibiotic Baxdela™ (delafloxacin) in the United States
  3. Melinta Therapeutics Announces Initiation of Program for Radezolid in Patients with Bacterial Vaginosis
  4. Blog Exposure - The Medicines Co. Completes Divestiture of Infectious Disease Business Unit to Melinta Therapeutics
  5. Melinta Therapeutics Completes Acquisition of The Medicines Company’s Infectious Disease Portfolio
  6. The Medicines Company Announces Closing of Divestiture of Infectious Disease Business Unit to Melinta Therapeutics
  7. Melinta Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference
  8. Melinta Therapeutics Appoints Lisa DeFrancesco as Senior Vice President of Investor Relations
  9. Blog Exposure - Melinta Therapeutics to Acquire Infectious Disease Business from The Medicines Co.
  10. Deerfield Supports Melinta Therapeutics Acquisition of The Medicines Company's Infectious Disease Business with a $240 million Commitment to Melinta and a $100 million Commitment to The Medicines Company
  11. The Medicines Company Announces Definitive Agreement to Sell its Infectious Disease Business Unit to Melinta Therapeutics
  12. Melinta Therapeutics Enters Into Agreement to Acquire Infectious Disease Business from The Medicines Company
  13. Melinta Therapeutics, Inc. – Value Analysis (NASDAQ:MLNT) : November 28, 2017
  14. Melinta Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : MLNT-US : November 27, 2017